Please assess the completion status of the following clinical trial:

Trial Title: Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients between the ages of 3 and 60 years, inclusive.~* Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.~* Presence of acute uncomplicated P. falciparum mono-infection confirmed by:~  1. Fever, as defined by axillary/tympanic temperature ≥37.5°C or oral/rectal temperature ≥38°C, or documented history of fever in the previous 24 hours and,~ 2. Positive microscopy of P. falciparum with parasite density between 1,000 and 100,000 asexual parasite count/µl of blood~* Written informed consent provided by patient and/or parent/guardian/spouse.~* Ability to swallow oral medication.~Exclusion Criteria:~* Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization Criteria 2000.~* Mixed Plasmodium infection.~* Severe vomiting or severe diarrhoea.~* Known history or evidence of clinically significant disorders.~* Presence of significant anaemia, as defined by Hb \<8 g/dL.~* Presence of febrile conditions caused by diseases other than malaria.~* Known history of hypersensitivity, allergic or adverse reactions to pyronaridine, mefloquine or artesunate or other artemisinins.~* Use of any other antimalarial agent within 2 weeks prior to start of the study as evidenced by positive urine test.~* Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the study period.~* Presence of significant renal or hepatic impairment.~* Receipt of an investigational drug within the past 4 weeks.~* Known active Hepatitis A IgM, Hepatitis B surface antigen or Hepatitis C antibody.~* Known seropositive HIV antibody.~* Previous participation in any clinical study with PA.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Pyronaridine - artesunate (Type: EXPERIMENTAL): Oral pyronaridine artesunate (180:60mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.
- Mefloquine plus artesunate (Type: ACTIVE_COMPARATOR): Mefloquine (250mg tablets) plus artesunate (100mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.

Based on this trial design, predict the completion outcome and termination type (if applicable).